Off-label prescribing of antipsychotics in adults, children and elderly individuals: A Systematic review of recent prescription trends

Current Pharmaceutical Design

Volumn 21, Issue 23, 2015, Pages 3280-3297

  Carton, Louise ^a,b   Cottencin, Olivier ^a,c   Lapeyre Mestre, Maryse ^d   Geoffroy, Pierre A ^e,f,g   Favre, Jonathan ^h   Simon, Nicolas ^i,j   Bordet, Régis ^b   Rolland, Benjamin ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CHU Lille   (France)

^c Univ Lille   (France)

^d Faculté de Médecine Centre Hospitalo universitaire   (France)

^e INSERM   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h UNIV LILLE   (France)

ⁱ AIX MARSEILLE UNIV   (France)

^j HÔPITAL SAINTE MARGUERITE   (France)

more..

Author keywords

Adults; Antipsychotics; Children; Elderly; Off label; Pharmacoepidemiology; Safety

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; QUETIAPINE; RISPERIDONE;

AGE DISTRIBUTION; AGITATION; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; DRUG INDICATION; DRUG SAFETY; HUMAN; INSOMNIA; MOOD DISORDER; OFF LABEL DRUG USE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; ADOLESCENT; ADULT; AGE; AGED; CHILD; CLINICAL PRACTICE; INAPPROPRIATE PRESCRIBING; MENTAL DISORDERS; MIDDLE AGED; PATIENT SAFETY; PRESCRIPTION; PSYCHOLOGY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIPSYCHOTIC AGENTS; CHILD; DRUG PRESCRIPTIONS; HUMANS; INAPPROPRIATE PRESCRIBING; MENTAL DISORDERS; MIDDLE AGED; OFF-LABEL USE; PATIENT SAFETY; PRACTICE PATTERNS, PHYSICIANS'; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84938630153     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150619092903     Document Type: Article

References (111)

1. [1]. Palmaro A, Bissuel R, Renaud N, et al. Off-label prescribing in pediatric outpatients. Pediatrics 2015; 135(1): 49-58.
2. [2]. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006; 166(9): 1021-6.
3. [3]. Malhi GS, Boyce P. Going forth in July? Off-label use in psychiatry. Aust N Z J Psychiatry 2011; 45(7): 507-8.
4. [4]. Adam D. Mental health: on the spectrum. Nature 2013; 496(7446): 416-8.
5. [5]. Verdoux H, Tournier M, Bégaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010; 121(1): 4-10.
6. [6]. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multipletreatments meta-analysis. Lancet 2013; 382(9896): 951-62.
7. [7]. Barbui C, Ciuna A, Nosé M, et al. Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient practice. Acta Psychiatr Scand 2004; 109(4): 275-8.
8. [8]. Citrome L, Kalsekar I, Guo Z, Laubmeier K, Hebden T. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis. Clin Ther 2013; 35(12): 1867-75.
9. [9]. Graziul C, Gibbons R, Alexander GC. Association between the commercial characteristics of psychotropic drugs and their off-label use. Med Care 2012; 50(11): 940-7.
10. [10]. Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the department of Veterans Affairs health care system. Psychiatr Serv Wash DC 2009; 60(9): 1175-81.
11. [11]. Leslie DL, Rosenheck R. Off-label use of antipsychotic medications in Medicaid. Am J Manag Care 2012; 18(3): e109-17.
12. [12]. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 2011; 20(2): 177-84.
13. [13]. Chen H, Reeves JH, Fincham JE, Kennedy WK, Dorfman JH, Martin BC. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia medicaid enrollees in 2001. J Clin Psychiatry 2006; 67(6): 972-82.
14. [14]. Weiss E, Hummer M, Koller D, Pharmd, Ulmer H, Fleischhacker WW. Off-label use of antipsychotic drugs. J Clin Psychopharmacol 2000; 20(6): 695-8.
15. [15]. Eguale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med 2012; 172(10): 781-8.
16. [16]. Barbui C, Danese A, Guaiana G, et al. Prescribing secondgeneration antipsychotics and the evolving standard of care in Italy. Pharmacopsychiatry 2002; 35(6): 239-43.
17. [17]. Martin-Latry K, Ricard C, Verdoux H. A one-day survey of characteristics of off-label hospital prescription of psychotropic drugs. Pharmacopsychiatry 2007; 40(3): 116-20.
18. [18]. Trifirò G, Spina E, Brignoli O, Sessa E, Caputi AP, Mazzaglia G. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. Eur J Clin Pharmacol 2005; 61(1): 47-53.
19. [19]. Walton SM, Schumock GT, Lee KV, Alexander GC, Meltzer D, Stafford RS. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy 2008; 28(12): 1443-52.
20. [20]. Hermes EDA, Sernyak M, Rosenheck R. Use of Second-Generation Antipsychotic Agents for Sleep and Sedation: A Provider Survey. SLEEP [Internet]. 2013 Apr 1 [cited 2013 Oct 1]; Available from: http://www.journalsleep.org/ViewAbstract.aspx?pid=28891
21. [21]. Camsar_ U, Viguera AC, Ralston L, Baldessarini RJ, Cohen LS. Prevalence of atypical antipsychotic use in psychiatric outpatients: comparison of women of childbearing age with men. Arch Womens Ment Health 2014; 17(6): 583-6.
22. [22]. Hartung DM, Zerzan J, Yamashita T, Tong S, Morden NE, Libby AM. Characteristics and trends of low-dose quetiapine use in two western state Medicaid programs. Pharmacoepidemiol Drug Saf 2014; 23(1): 87-94.
23. [23]. Philip NS, Mello K, Carpenter LL, Tyrka AR, Price LH. Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Ann Clin Psychiatry Off J Am Acad Clin Psychiatry 2008; 20(1): 15-20.
24. [24]. Bauer MS, Lee A, Li M, Bajor L, Rasmusson A, Kazis LE. Offlabel use of second generation antipsychotics for post-traumatic stress disorder in the Department of Veterans Affairs: time trends and sociodemographic, comorbidity, and regional correlates. Pharmacoepidemiol Drug Saf 2014; 23(1): 77-86.
25. [25]. Pascual JC, Martín-Blanco A, Soler J, et al. A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines. Int Clin Psychopharmacol 2010; 25(6): 349-55.
26. [26]. Boonstra G, Grobbee DE, Hak E, Kahn RS, Burger H. Initiation of antipsychotic treatment by general practitioners. a case-control study. J Eval Clin Pract 2011; 17(1): 12-7.
27. [27]. Atik L, Erdogan A, Karaahmet E, et al. Antipsychotic prescriptions in a university hospital outpatient population in Turkey: a retrospective database analysis, 2005-2006. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(4): 968-74.
28. [28]. Wolfsperger M, Greil W, Rössler W, Grohmann R. Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. J Affect Disord 2007; 99(1-3): 9-17.
29. [29]. Pringsheim T, Gardner DM. Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study. CMAJ Open 2014; 2(4): E225-32.
30. [30]. Monasterio E, McKean A. Off-label use of atypical antipsychotic medications in Canterbury, New Zealand. N Z Med J 2011; 124(1336): 24-9.
31. [31]. Wu CH, Wang CC, Katz AJ, Farley J. National trends of psychotropic medication use among patients diagnosed with anxiety disorders: Results from Medical Expenditure Panel Survey 2004-2009. J Anxiety Disord 2013; 27(2): 163-70.
32. [32]. Comer JS, Mojtabai R, Olfson M. National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders. Am J Psychiatry 2011; 168(10): 1057-65.
33. [33]. Demland J, Jing Y, Kelton C, Guo J, Wigle P. Use pattern and offlabel use of atypical antipsychotics in bipolar disorder, 1998-2002. Am Health Drug Benefits 2009; 2(4): 184-91.
34. [34]. Kogut SJ, Yam F, Dufresne R. Prescribing of antipsychotic medication in a medicaid population: use of polytherapy and off-label dosages. J Manag Care Pharm JMCP 2005; 11(1): 17-24.
35. [35]. Hartung DM, Wisdom JP, Pollack DA, et al. Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients. J Clin Psychiatry 2008; 69(10): 1540-7.
36. [36]. Huffman JC, Chang TE, Durham LE, Weiss AP. Antipsychotic polytherapy on an inpatient psychiatric unit: how does clinical practice coincide with Joint Commission guidelines? Gen Hosp Psychiatry 2011; 33(5): 501-8.
37. [37]. Lunsky Y, Elserafi J. Antipsychotic medication prescription patterns in adults with developmental disabilities who have experienced psychiatric crisis. Res Dev Disabil 2012; 33(1): 32-8.
38. [38]. Aparasu RR, Jano E, Bhatara V. Concomitant antipsychotic prescribing in US outpatient settings. Res Soc Adm Pharm 2009; 5(3): 234-41.
39. [39]. Centorrino F, Ventriglio A, Vincenti A, Talamo A, Baldessarini RJ. Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. Hum Psychopharmacol 2010; 25(2): 179-86.
40. [40]. Sankaranarayanan J, Puumala SE. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors. Clin Ther 2007; 29(4): 723-41.
41. [41]. Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ. Prevalence, utilization patterns, and predictors of antipsychoticpolypharmacy: experience in a multistate Medicaid Population, 1998-2003. Clin Ther 2007; 29(1): 183-95.
42. [42]. Pickar D, Vinik J, Bartko JJ. Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PloS One 2008; 3(9): e3150.
43. [43]. Baeza I, de la Serna E, Calvo-Escalona R, et al. Antipsychotic use in children and adolescents: a 1-year follow-up study. J Clin Psychopharmacol 2014; 34(5): 613-9.
44. [44]. Procyshyn RM, Su J, Elbe D, et al. Prevalence and patterns of antipsychotic use in youth at the time of admission and discharge from an inpatient psychiatric facility. J Clin Psychopharmacol 2014; 34(1): 17-22.
45. [45]. Marsanic VB, Dodig-Curkovic K, Juretic Z. Outpatient treatment of children and adolescents with antipsychotic drugs in Croatia. Nord J Psychiatry 2012; 66(1): 2-7.
46. [46]. Pathak P, West D, Martin BC, Helm ME, Henderson C. Evidencebased use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv Wash DC 2010; 61(2): 123-9.
47. [47]. Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood) 2009; 28(5): w770-81.
48. [48]. Rodday AM, Parsons SK, Correll CU, et al. Child and adolescent psychiatrists’ attitudes and practices prescribing second generation antipsychotics. J Child Adolesc Psychopharmacol 2014; 24(2): 90-3.
49. [49]. Rawal PH, Lyons JS, MacIntyre JC 2nd, Hunter JC. Regional variation and clinical indicators of antipsychotic use in residential treatment: a four-state comparison. J Behav Health Serv Res 2004; 31(2): 178-88.
50. [50]. Ronsley R, Scott D, Warburton WP, et al. A population-based study of antipsychotic prescription trends in children and adolescents in British Columbia, from 1996 to 2011. Can J Psychiatr Rev Can Psychiatry 2013; 58(6): 361-9.
51. [51]. Gilat Y, Ben-Dor DH, Magen A, et al. Trends in prescribing of psychotropic medications for inpatient adolescents in Israel: A 10 years retrospective analysis. Eur Psychiatry 2011; 26(4): 265-9.
52. [52]. Hsu YC, Chien IC, Tan HK-L, et al. Trends, correlates, and disease patterns of antipsychotic use among children and adolescents in Taiwan. Soc Psychiatr Psychiatr Epidemiol 2013; 48(12): 1889-96.
53. [53]. Alessi-Severini S, Biscontri RG, Collins DM, Sareen J, Enns MW. Ten years of antipsychotic prescribing to children: a Canadian population-based study. Can J Psychiatry 2012; 57(1): 52-8.
54. [54]. Liu X, Kubilis P, Xu D, Bussing R, Winterstein AG. Psychotropic drug utilization in children with concurrent attentiondeficit/ hyperactivity disorder and anxiety. J Anxiety Disord 2014; 28(6): 530-6.
55. [55]. Scheifes A, de Jong D, Stolker JJ, Nijman HLI, Egberts TCG, Heerdink ER. Prevalence and characteristics of psychotropic drug use in institutionalized children and adolescents with mild intellectual disability. Res Dev Disabil 2013; 34(10): 3159-67.
56. [56]. Bachmann CJ, Manthey T, Kamp-Becker I, Glaeske G, Hoffmann F. Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany. Res Dev Disabil 2013; 34(9): 2551-63.
57. [57]. Doey T, Handelman K, Seabrook JA, Steele M. Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Can J Psychiatry 2007; 52(6): 363-8.
58. [58]. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000; 283(8): 1025-30.
59. [59]. Zito JM, Safer DJ, Valluri S, Gardner JF, Korelitz JJ, Mattison DR. Psychotherapeutic medication prevalence in Medicaid-insured preschoolers. J Child Adolesc Psychopharmacol 2007; 17(2): 195-203.
60. [60]. Cascade EF, Kalali AH, Citrome L. Antipsychotic use varies by patient age. Psychiatry Edgmont Pa Townsh 2007; 4(7): 20-3.
61. [61]. Owens JA, Rosen CL, Mindell JA, Kirchner HL. Use of pharmacotherapy for insomnia in child psychiatry practice: A national survey. Sleep Med 2010; 11(7): 692-700.
62. [62]. Koelch M, Prestel A, Singer H, et al. Psychotropic medication in children and adolescents in Germany: prevalence, indications, and psychopathological patterns. J Child Adolesc Psychopharmacol 2009; 19(6): 765-70.
63. [63]. Penfold RB, Kelleher KJ, Wang W, Strange B, Pajer K. Pediatric uptake of a newly available antipsychotic medication. Pediatrics 2010; 125(3): 475-82.
64. [64]. Kreider AR, Matone M, Bellonci C, et al. Growth in the Concurrent Use of Antipsychotics With Other Psychotropic Medications in Medicaid-Enrolled Children. J Am Acad Child Adolesc Psychiatry 2014; 53(9): 960-70.
65. [65]. Murphy AL, Gardner DM, Cooke C, Kisely S, Hughes J, Kutcher SP. Prescribing trends of antipsychotics in youth receiving income assistance: results from a retrospective population database study. BMC Psychiatry 2013; 13(1): 198.
66. [66]. Azermai M, Elseviers M, Petrovic M, van Bortel L, Stichele RV. Assessment of antipsychotic prescribing in Belgian nursing homes. Int Psychogeriatr IPA 2011; 23(8): 1240-8.
67. [67]. Larrayadieu A, Abellan van Kan G, Piau A, et al. Associated factors with antipsychotic use in assisted living facilities: a crosssectional study of 4367 residents. Age Ageing 2011; 40(3): 368-75.
68. [68]. Kamble P, Sherer J, Chen H, Aparasu R. Off-label use of secondgeneration antipsychotic agents among elderly nursing home residents. Psychiatr Serv Wash DC 2010; 61(2): 130-6.
69. [69]. Stevenson DG, Decker SL, Dwyer LL, et al. Antipsychotic and benzodiazepine use among nursing home residents: findings from the 2004 national nursing home survey. Am J Geriatr Psychiatry 2010; 18(12): 1078-92.
70. [70]. Kamble P, Chen H, Sherer J, Aparasu RR. Antipsychotic drug use among elderly nursing home residents in the United States. Am J Geriatr Pharmacother 2008; 6(4): 187-97.
71. [71]. Liperoti R, Mor V, Lapane KL, Pedone C, Gambassi G, BernabeiR. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003; 64(9): 1106-12.
72. [72]. De Mauleon A, Sourdet S, Renom-Guiteras A, et al. Associated factors with antipsychotic use in long-term institutional care in eight european countries: results from the right time place care study. J Am Med Dir Assoc 2014; 15(11): 812-8.
73. [73]. Okumura Y, Togo T, Fujita J. Trends in use of psychotropic medications among patients treated with cholinesterase inhibitors in Japan from 2002 to 2010. Int Psychogeriatr IPA 2015; 27(3): 407-15.
74. [74]. Tiller J, Ames D, Brodaty H, et al. Antipsychotic use in the elderly: what doctors say they do, and what they do. Australas J Ageing 2008; 27(3): 134-42.
75. [75]. Simoni-Wastila L, Wei Y-J, Luong M, et al. Quality of psychopharmacological medication use in nursing home residents. Res Soc Adm Pharm 2014; 10(3): 494-507.
76. [76]. Dolder CR, McKinsey J. Quetiapine for sleep in patients with dementia. Consult Pharm J Am Soc Consult Pharm 2010; 25(10): 676-9.
77. [77]. Harding R, Peel E. “He was like a zombie”: off-label prescription of antipsychotic drugs in dementia. Med Law Rev 2013; 21(2): 243-77.
78. [78]. Calvó-Perxas L, de Eugenio RM, Marquez-Daniel F, et al. Profile and variables related to antipsychotic consumption according to dementia subtypes. Int Psychogeriatr IPA 2012; 24(6): 940-7.
79. [79]. Kales HC, Zivin K, Kim HM, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry 2011; 68(2): 190-7.
80. [80]. Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use.Arch Intern Med 2010; 170(1): 96-103.
81. [81]. Desai VCA, Heaton PC, Kelton CML. Impact of the Food and Drug Administration’s antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settings. Alzheimers Dement 2012; 8(5): 453-7.
82. [82]. Franchi C, Tettamanti M, Marengoni A, et al. Changes in trend of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian Medicines Agency. Results from the EPIFARM-Elderly Project. Eur Neuropsychopharmacol 2012; 22(8): 569-77.
83. [83]. Chiabrando G, Bianchi S, Poluzzi E, Montanaro N, Scanavacca P. Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara. Eur J Clin Pharmacol 2010; 66(7): 661-9.
84. [84]. Gareri P, De Fazio P, Manfredi VGL, De Sarro G. Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol 2014; 34(1): 109-23.
85. [85]. Shah C, Sharma T, Kablinger A. Controversies in the use of second generation antipsychotics as sleep agent. Pharmacol Res Off J Ital Pharmacol Soc 2014; 79: 1-8
86. [86]. Rosenbluth M, Sinyor M. Off-label use of atypical antipsychotics in personality disorders. Expert Opin Pharmacother 2012; 13(11): 1575-85.
87. [87]. Roehrs T, Roth T. Insomnia pharmacotherapy. Neurother J Am Soc Exp Neurother 2012; 9(4): 728-38.
88. [88]. Pies R. Should psychiatrists use atypical antipsychotics to treat nonpsychotic anxiety? Psychiatry Edgmont Pa Townsh 2009; 6(6): 29-37.
89. [89]. Scheltema Beduin A, de Haan L. Off-label second generation antipsychotics for impulse regulation disorders: a review. Psychopharmacol Bull 2010; 43(3): 45-81.
90. [90]. Bullock R. Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Curr Med Res Opin 2005; 21(1): 1-10.
91. [91]. Patten SB, Waheed W, Bresee L. A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents. Can J Psychiatry 2012; 57(12): 717-21.
92. [92]. Seida JC, Schouten JR, Boylan K, et al. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics 2012; 129(3): e771-84.
93. [93]. Caccia S, Clavenna A, Bonati M. Antipsychotic drug toxicology in children. Expert Opin Drug Metab Toxicol 2011; 7(5): 591-608.
94. [94]. Rasimas JJ, Liebelt EL. Adverse effects and toxicity of the atypical antipsychotics: what is important for the pediatric emergency medicine practitioner. Clin Pediatr Emerg Med 2012; 13(4): 300-10.
95. [95]. McKean A, Monasterio E. Off-Label Use of Atypical Antipsychotics. CNS Drugs 2012; 26(5): 383-90.
96. [96]. Monasterio E, McKean A. Quetiapine use: Science or clever marketing? Aust N Z J Psychiatry 2013; 47(1): 96-7.
97. [97]. Geoffroy PA, Etain B, Henry C, Bellivier F. Combination therapy for manic phases: a critical review of a common practice. CNS Neurosci Ther 2012; 18(12): 957-64.
98. [98]. Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry J Ment Sci 2010; 197(4): 266-71.
99. [99]. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360(3): 225-35.
100. [100]. Cates ME, Jackson CW, Feldman JM, Stimmel AE, Woolley TW. Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients. Community Ment Health J 2009; 45(4): 251-4.
101. [101]. Birnbaum ML, Saito E, Gerhard T, et al. Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications. Curr Psychiatry Rep 2013; 15(8): 382.
102. [102]. Egberts KM, Mehler-Wex C, Gerlach M. Therapeutic drug monitoring in child and adolescent psychiatry. Pharmacopsychiatry 2011; 44(6): 249-53.
103. [103]. Mensonides-Harsema M, Otte A. European regulatory framework on the use and development of pharmaceuticals and radiopharmaceuticals for pediatrics. Hell J Nucl Med 2011; 14(1): 43-8.
104. [104]. Mehler-Wex C, Kölch M, Kirchheiner J, Antony G, Fegert JM, Gerlach M. Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child Adolesc Psychiatry Ment Health 2009; 3(1): 14.
105. [105]. Jeste DV, Blazer D, Casey D, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2008; 33(5): 957-70.
106. [106]. Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia- related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry 2008; 69(6): 889-98.
107. [107]. Mesgarpour B, Müller M, Herkner H. Search strategies-identified reports on “off-label” drug use in MEDLINE. J Clin Epidemiol 2012; 65(8): 827-34.
108. [108]. Zito JM, Safer DJ, De Jong-Van, Den Berg LTW, et al. A threecountry comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2008; 2(1): 26.
109. [109]. Devulapalli KK, Nasrallah HA. An analysis of the high psychotropic off-label use in psychiatric disorders The majority of psychiatric diagnoses have no approved drug. Asian J Psychiatry 2009; 2(1): 29-36.
110. [110]. Mello MM, Messing NA. Restrictions on the use of prescribing data for drug promotion. N Engl J Med 2011; 365(13): 1248-54.
111. [111]. Rolland B, Bordet R, Cottencin O. Alcohol-dependence: the current French craze for baclofen. Addict Abingdon Engl 2012; 107(4): 848-9.